FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.115,04 +1.769,64 (+3,09%)
Monopar Therapeutics Inc. (1IY.F)
| Chiusura precedente | 0,6450 |
| Aperto | 0,6000 |
| Denaro | 0,6300 x N/D |
| Lettera | 0,6950 x N/D |
| Min-Max giorno | 0,5850 - 0,6500 |
| Intervallo di 52 settimane | 0,2400 - 1,4500 |
| Volume | |
| Media Volume | 494 |
| Capitalizzazione | 11,83M |
| Beta (5 anni mensile) | 1,20 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5700 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 40,67 |
GlobeNewswireMonopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale Club, New York City, New York https://www.roth.com/conferences/upcom
- GlobeNewswire
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take
- GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced second quarter 2023 financial results and summarized recent developments. Recent Developm
